Trial Profile
Randomized, double-blind, Phase 2 study to evaluate the efficacy and the safety of OSE-127 versus placebo in subjects with moderate to severe active ulcerative colitis who have failed or are intolerant to previous treatment(s)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Jan 2024
Price :
$35
*
At a glance
- Drugs Lusvertikimab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms CoTikiS
- Sponsors OSE Immunotherapeutics
- 19 Jan 2024 According to an OSE Immunotherapeutics media release, first results (from induction to week 10 and after 6 months of maintenance) are expected in mid-2024.
- 19 Jan 2024 According to an OSE Immunotherapeutics media release, patient enrollment expected in Q1 2024 as the trial was redirected towards new clinical centers in countries further west in Europe concerning patients naive to biological treatments, who are much more numerous in the countries from Eastern Europe.
- 27 Sep 2023 According to an OSE Immunotherapeutics media release, Last patient enrollment is expected for Q4 2023.